Evaluating The Association Between Serum Hsp27 Antibody and Hypertension in Patients without Underlying Cardiovascular Disease

Document Type : Original Article


1 Immunology Research Center, BuAli Research Institute, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

4 International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

7 Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad,Iran.

8 Norwegian Center for E-Health Research, University Hospital of North Norway, Tromsø, Norway.

9 Department of Biochemistery and Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

10 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

11 Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

12 Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.

13 Metabolic Syndrome Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: An association between heat shock protein 27 (Hsp27) antigen with cardiovascular risk factors has been shown previously. Furthermore, higher levels of serum anti-HSP27 antibodies are also related to higher cardiovascular morbidity and mortality. In the current study, we looked at the relationship between serum Hsp27 antibodies and hypertension, as an important cardiovascular risk factor, in individuals without evidence of cardiovascular disease (CVD).
Methods: A sub-population of hypertensive patients (HTN+) without underlying CVD were recruited from the Mashhad stroke and atherosclerosis heart disease (MASHAD) study to assess the association between serum Hsp27 antibodies and hypertension; independent of other cardiovascular risk factors. A total of 1599 people were studied of whom 288 individuals had hypertension and 1311 were used as controls (HTN-).
Results: Mean serum Hsp27 antibody titers were 0.20 (0.27) OD in the whole population sample and was not significantly different in the normotensive (HTN-) compared to HTN+ individuals with different degrees of hypertension.
Conclusion: There were no significant associations between serum anti-Hsp27 concentrations and either the presence or severity of hypertension. Future studies are warranted to explore the association of anti-Hsp27 antibody and antigen levels and other cardiovascular risk factors.


  1. Ferns G, Shams S, Shafi S. Heat shock protein 27: its potential role in vascular disease. International journal of experimental pathology. 2006 Aug;87(4):253-74.
  2. Mehlen P, Hickey E, Weber LA, Arrigo AP. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFα in NIH-3T3-ras cells. Biochemical and biophysical research communications. 1997 Dec 8;241(1):187-92.
  3. Ciocca DR, Oesterreich S, Chamness GC, MCGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27000 (Hsp27): a review. JNCI: Journal of the National Cancer Institute. 1993 Oct 6;85(19):1558-70.
  4. Akamatsu S, Nakajima K, Ishisaki A, Matsuno H, Tanabe K, Takei M, et al. Vasopressin phosphorylates HSP27 in aortic smooth muscle cells. Journal of cellular biochemistry. 2004 Aug 15;92(6):1203-11.
  5. Hirade K, Kozawa O, Tanabe K, Niwa M, Matsuno H, Oiso Y, et al. Thrombin stimulates dissociation and induction of HSP27 via p38 MAPK in vascular smooth muscle cells. American Journal of Physiology-Heart and Circulatory Physiology. 2002 Sep 1;283(3):H941-8.
  6. Garrido C, Bruey JM, Fromentin A, Hammann A, Patrick Arrigo A, Solary E. HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9. The FASEB Journal. 1999 Nov;13(14):2061-70.
  7. Charette SJ, Lavoie JN, Lambert H, Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Molecular and cellular biology. 2000 Oct 15;20(20):7602-12.
  8. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell cycle. 2006 Nov 15;5(22):2592-601.
  9. Loktionova SA, Kabakov AE. Phosphatase inhibitors prevent HSP27 dephosphorylation, destruction of stress fibrils, and morphological changes in endothelial cells during ATP depletion. Bulletin of Experimental Biology and Medicine. 2001 Sep;132:914-7.
  10. Loktionova SA, Kabakov AE. Protein phosphatase inhibitors and heat preconditioning prevent Hsp27 dephosphorylation, F-actin disruption and deterioration of morphology in ATP-depleted endothelial cells. FEBS letters. 1998 Aug 21;433(3):294-300.
  11. Hirano S, Rees RS, Yancy SL, Welsh MJ, Remick DG, Yamada T, et al. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of HSP27 in vivo. Cell biology and toxicology. 2004 Feb;20:1-4.
  12. Aghasizadeh M, Samadi S, Sahebkar A, Miri‐Moghaddam E, Esmaily H, Souktanloo M, et al. Serum HDL cholesterol uptake capacity in subjects from the MASHAD cohort study: Its value in determining the risk of cardiovascular endpoints. Journal of Clinical Laboratory Analysis. 2021 Jun;35(6):e23770.
  13. Arata S, Hamaguchi S, Nose K. Effects of the overexpression of the small heat shock protein, HSP27, on the sensitivity of human fibroblast cells exposed to oxidative stress. Journal of cellular physiology. 1995 Jun;163(3):458-65.
  14. Arrigo AP, Virot S, Chaufour S, Firdaus W, Kretz-Remy C, Diaz-Latoud C. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxidants & redox signaling. 2005 Mar 1;7(3-4):414-22.
  15. De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-α induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. The Journal of Immunology. 2000 Oct 1;165(7):3951-8.
  16. Chen Y, Ross BM, Currie RW. Heat shock treatment protects against angiotensin II–induced hypertension and inflammation in aorta. Cell stress & chaperones. 2004 Mar;9(1):99.
  17. Xu Q, Li DG, Holbrook NJ, Udelsman R. Acute hypertension induces heat-shock protein 70 gene expression in rat aorta. Circulation. 1995 Sep 1;92(5):1223-9.
  18. Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004 Oct 12;110(15):2216-9.
  19. Wick G. The heat is on: heat-shock proteins and atherosclerosis. Circulation. 2006 Aug 29;114(9):870-2.
  20. Ghayour-Mobarhan M, Saber H, Ferns GA. The potential role of heat shock protein 27 in cardiovascular disease. Clinica chimica acta. 2012 Jan 18;413(1-2):15-24.
  21. Park KJ, Gaynor RB, Kwak YT. Heat shock protein 27 association with the IκB kinase complex regulates tumor necrosis factor α-induced NF-κB activation. Journal of Biological Chemistry. 2003 Sep 12;278(37):35272-8.
  22. Makowski GS. Advances in clinical chemistry: Gulf Professional Publishing; 2005.
  23. Tavallaie S, Rahsepar AA, Abdi H, Moohebati M, Moodi F, Pourghadamyari H, et al. Association between indices of body mass and antibody titers to heat-shock protein-27 in healthy subjects. Clinical biochemistry. 2012 Jan 1;45(1-2):144-7.
  24. Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clinica chimica acta. 2008 Sep 1;395(1-2):42-6.
  25. Pourghadamyari H, Moohebati M, Parizadeh SM, Falsoleiman H, Dehghani M, Fazlinezhad A, et al. Serum antibody titers against heat shock protein 27 are associated with the severity of coronary artery disease. Cell Stress and Chaperones. 2011 May;16:309-16.
  26. Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. Journal of clinical lipidology. 2012 Sep 1;6(5):413-26.
  27. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SM, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. International journal of public health. 2015 Jul;60:561-72.
  28. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ. Human blood pressure determination by sphygmomanometry. Circulation. 1993 Nov;88(5):2460-70.
  29. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. hypertension. 2003 Dec 1;42(6):1206-52.
  30. Sahebkar A, Pourghadamyari H, Moohebati M, Parizadeh SM, Falsoleiman H, Dehghani M, et al. A cross-sectional study of the association between heat shock protein 27 antibody titers, pro-oxidant–antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease. Clinical biochemistry. 2011 Dec 1;44(17-18):1390-5.
  31. Bell K, Twiggs J, Olin BR, Date IR. Hypertension: the silent killer: updated JNC-8 guideline recommendations. Alabama pharmacy association. 2015 Jun 1;334:4222.
  32. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23;121(7):e46-215.
  33. Ghayour-Mobarhan M, Rahsepar AA, Tavallaie S, Rahsepar S, Ferns GA. The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies. Advances in clinical chemistry. 2009 Jan 1;48:27-72.
  34. Ghayour‐Mobarhan M, Sahebkar A, Parizadeh SM, Moohebati M, Tavallaie S, RezaKazemi‐Bajestani SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. International journal of experimental pathology. 2008 Jun;89(3):209-15.
  35. Mouhebati M, Ghayour-Mobarhan M, Parizadeh S, Sahebkar A, Tavallaie S, Kazemi-Bajestani S, et al. ANTIBODY TITERS TO HEAT SHOCK PROTEIN 27 ARE ELEVATED IN PATIENTS WITH MYOCARDIAL INFARCTION. Atherosclerosis (Supplements)(Component). 2008;1(9):152.
  36. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in lipid research. 2014 Oct 1;56:47-66.
  37. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. Journal of cardiovascular risk. 1996 Apr;3(2):213-9.
  38. KUNEŠ J, Poirier M, Tremblay J, Hamet P. Expression of hsp70 gene in lymphocytes from normotensive and hypertensive humans. Acta physiologica scandinavica. 1992 Nov;146(3):307-11.
  39. Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin T, Frostegård J. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. Journal of hypertension. 2002 Sep 1;20(9):1815-20.
  40. Molvarec A, Prohászka Z, Nagy B, Szalay J, Füst G, Karádi I, et al. Association of elevated serum heat-shock protein 70 concentration with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia: a case–control study. Journal of human hypertension. 2006 Oct;20(10):780-6.